Endo is a pharmaceutical company based in the United States. It was founded in 1920 by Dr. Roger L.

Byhre, initially focusing on producing contraceptives. Over the years, the company expanded its product portfolio to include various therapeutic areas such as pain management, urology, neurology, and oncology. The company's headquarters are located in Dublin, Ireland.

Endo has a strong presence in the United States, with several manufacturing facilities and offices spread across the country. It also has operations in other regions, including Europe, Canada, and Latin America. Endo offers a wide range of products and services.

Its pharmaceutical segment includes both branded and generic drugs, catering to the needs of patients and healthcare professionals. The company's portfolio consists of medications for pain relief, hormone replacement therapy, urological disorders, ADHD, and chemotherapy-induced nausea, among others. In terms of subsidiaries, Endo has noteworthy acquisitions and partnerships.

In 2014, the company acquired Paladin Labs, a leading Canadian specialty pharmaceutical company. This acquisition expanded Endo's presence in Canada and strengthened its global market position. Endo also has joint ventures with other companies to collaborate on research and development efforts.

Endo has established a strong market position, particularly in the pain management segment. It has faced competition from other pharmaceutical companies, but its diverse product portfolio and emphasis on innovation have contributed to its success. The company has consistently ranked among the top players in the global pharmaceutical industry.

In recent years, Endo has implemented changes to its strategy and product lineup. To adapt to the evolving healthcare landscape, the company has focused on developing and marketing innovative and differentiated products. It has also pursued strategic acquisitions and partnerships to expand its product offerings and market reach.

As of the latest information, Endo continues to evolve and grow. It remains committed to delivering high-quality medications and improving patient outcomes. The company actively engages in research and development to address unmet medical needs and enhance its product portfolio.

Endo strives to maintain a strong market position and drive sustainable growth in the pharmaceutical industry